Posted on 09/03/2022 1:41:30 PM PDT by nickcarraway
A Chinese research team has developed a nanomaterial that can find Sars-CoV-2 viruses in a living cell and remove them.
Unlike most existing Covid-19 drugs, the material can inhibit infections from all major variants including Alpha, Beta, Delta and Omicron with high biosafety, the researchers said.
“It can be a promising therapy to fight the pandemic in the future,” said a researcher involved in the study who asked not to be named.
The findings were published in August in Nature Nanotechnology.
Researchers from the Shenzhen Institute of Advanced Technology, National Centre for Nanoscience and Technology, Institute of High Energy Physics, and the Kunming Institute of Zoology – all under the Chinese Academy of Sciences – contributed to the work.
Nanomaterials are extremely small – a single nanometre is one billionth of a metre. The structure of the material – called CIPS because it is made of copper, indium, phosphorus and sulphur – takes the form of nanosheets that are about 200 nanometres, around the size of two viral particles.
Normally, the Sars-CoV-2 virus invades human cells with help of the spike protein on its surface. The spike protein binds with the ACE2 protein on the surface of the human cell in the same way a key opens a lock, thus allowing the virus to invade the host cell.
CIPS, however, is capable of selectively binding with the virus’ spike protein, resulting in the infection process being blocked.
“It serves as a trap for the virus,” the National Centre for Nanoscience and Technology said on its website.
Once CIPS has captured the virus, it forms a stable complex. The complex is then recognised and eliminated by the host’s macrophages, large white blood cells in the human immune system that digest foreign substances.
“Experiments show that CIPS effectively inhibits infection in cells, organoids and mice, and effectively relieves lung inflammation in mice caused by Sars-CoV-2 infection,” the paper said.
The effectiveness of current vaccines and antibodies being used against Sars-CoV-2 decline against variants like Omicron . While most antibodies are designed to bind with one single location on the virus, the mutation in Omicron variants may change the structure of the surface. CIPS can bind to multiple sites at the same time.
More than 1,000 new coronavirus mutant strains have been discovered so far. Though the Chinese team cannot test CIPS materials on all strains, they found CIPS were highly effective against all variants of concern – Alpha, Beta, Delta and Omicron.
Good biocompatibility is a prerequisite for the safe application of nanomaterial. Researchers studied the absorption, distribution, metabolism and excretion process of CIPS in mice and found the material had high biodegradability.
“Mice inhale CIPS through nasal drop and after seven days, it shows almost entire elimination of CIPS from the lung of mice,” the study said.
The biodegradability and biosafety of CIPS nanomaterials indicate it has good potential and application value, but it must still be tested through a series of clinical trials before it can be it ready for use in humans, the unnamed researcher said.
“The safety assessment of anti-Covid-19 drugs includes a test for toxicity to the organ and immune system, a test for toxicity that causes deformities, and a test for allergies. The process is long and expensive, usually done by pharmaceutical companies,” they added.
The good news is that the nanomaterials could be relatively cheap enough for mass production and widespread applications.
“The nanomaterial could be used as a decontamination agent or surface-coating material to reduce Sars-CoV-2 infectivity,” said the researcher.
Too late, the pandemic is over.
Tiny discovery. Did Xi pull down his pants at the lab?
LOL, and the side effects?
Fool me once shame on you fool me twice Darwin award.
The deep state does not want a cure. Crickets. Nothing will happen.
Anything that comes out of China is a scam.
***********
Well they seem to be scamming the USA and the rest of the
world without much effort. They got something going for them
That’s the answer! Give me a good big dose of the Chinese nanoparticles!
It’s a trap.
A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination
https://www.nature.com/articles/s41565-022-01177-2
*
Watch out for the poisoned fake toothpaste.
Conclusions
Here we have described the 2D CIPS NS as an effective nano-glue capable of selectively capturing the SARS-CoV-2 virus by binding its S protein, thereby inhibiting infection of host cells. The binding affinity of CIPS to the S-protein RBD is <1 pM, suggesting the formation of very stable complexes. The effective binding of CIPS to eight of the eleven ACE2-binding amino acid residues of the SARS-CoV-2 RBD accounts for the efficient inhibition of viral infectivity. The RBD mutations displayed by SARS-CoV-2 VOCs do not affect their binding to CIPS, and indeed CIPS proved broadly effective in inhibiting all the viral VOCs, with efficacy evident in both preventive treatment and therapeutic strategies in vitro and in vivo. In addition, the similarity of the RBD of SARS-CoV-2 to the RBDs of other coronaviruses (for example, SARS) suggests that CIPS is also potentially useful in broadly inhibiting coronavirus infectivity (Supplementary Fig. 18).
Notably, the affinity of CIPS for SARS-CoV-2 RBDs (KD < 1 pM) is substantially higher than that of therapeutic mAbs, which have an affinity in the range from 23 pM to 100 nM25,28,42, similar to the binding affinity between the RBD and ACE2 (11–17.4 nM in our hands, 14.7 nM reported for S-protein binding to ACE236). This suggests that only a few of the currently available mAbs may have sufficient affinity for the RBD to efficiently compete with its binding to ACE2, and that their efficacy against different VOCs varies greatly, with a substantial loss of efficacy for the Omicron VOC, which displays 15 mutations in the RBD15. Thus, compared with mAbs, CIPS displays a higher affinity for RBD and a broader specificity, which enable it to bind and neutralize all SARS-CoV-2 VOCs.
CIPS has been found safe and biocompatible both in vitro (Supplementary Fig. 4) and in vivo (Extended Data Fig. 7, Supplementary Figs. 19 and 20, and Supplementary Tables 8 and 9), being quickly removed from the lung, most probably degraded by macrophages, and eliminated through urine (Extended Data Fig. 7d). After intranasal administration, CIPS does not enter the blood stream (Extended Data Fig. 7), is unable to cause haemolysis, does not induce inflammatory activation of macrophages and is unable to bind IgG (Supplementary Fig. 21). The SARS-CoV-2 adsorbed on CIPS can be efficiently phagocytosed by macrophages, shuttled to phagolysosomes and completely degraded together with its carrier. Another important consequence of the CIPS-dependent virus uptake by macrophages and its intracellular degradation is the expected generation of viral peptides and their presentation in the context of MHC II molecules, that is, the pathway of antigen presentation that induces a strong antibody response. Thus, the capacity of CIPS to direct the virus to macrophages has the double advantage of promoting viral destruction and triggering antiviral adaptive immunity.
Thus, CIPS is a safe, biocompatible and biodegradable 2D NM capable of inhibiting infection and promoting the elimination of SARS-CoV-2 (Fig. 6). The binding between CIPS and the SARS-CoV-2 S-protein RBD is ~10,000-fold stronger than the affinity of the virus for ACE2, suggesting that the CIPS-captured virus will not be released and will not infect cells. Notably, CIPS binding is 23- to 100-fold stronger than that of the best mAbs, and its broad capacity for RBD binding makes it equally effective against all the tested VOCs, as well as for other coronaviruses. Its broad-spectrum efficacy, storage stability and good biocompatibility make CIPS a promising anti-SARS-CoV-2 drug candidate. The viscous flypaper-like and selective binding capacity of CIPS for the SARS-CoV-2 S protein also makes it particularly promising as a surface-coating material and decontamination agent, to contain viral spread and increase safety during handling in laboratory and clinical settings.
No thanks.
The deep states cure is the next bio attack.
Hard pass.
This is fantastic news. Cudos should go to the person who discovered it!
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.